TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35477518
Drug: Iberdomide (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.15 mg, 0.3 mg, 0.45 mg)
Study: 33323914
Drug: Discordant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discordant treatment (DisTG)
Study: 33323914
Drug: Concordant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concordant treatment (ConTG)
Study: 34700768
Drug: Tumor Treating
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Treating Fields (TTFields) with individualized array placement, delivering doses over 2.5 mW/cm3
Study: 34700768
Drug: Patient-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific treatment planning using numerical simulations
Study: 34154034
Drug: Treatment failure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failure patients
Study: 34138638
Drug: Imetelstat 9.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat 9.4 mg/kg
Study: 34138638
Drug: Imetelstat 4.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat 4.7 mg/kg
Study: 35718440
Drug: 1% curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% curcumin nanomicelle gel
Study: 34607863
Drug: Online chronic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online chronic disease self-management programme (CDSMP) plus medication adherence tools
Study: 35322981
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium (5 mL)
Study: 36449375
Drug: Subcutaneous fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fully closed-loop (FCL; CamAPS HX) insulin therapy
Study: 36449375
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) insulin therapy
Study: 33719017
Drug: Intranasal glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glulisine 20 IU twice daily
Study: 32612186
Drug: Avocado pulp
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocado pulp (600 mg in capsule)
Study: 32804855
Drug: 400 µg CrPic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg CrPic tablets (200 µg in two divided doses) daily for 12 weeks
Study: 32087795
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 25 mg once a day
Study: 36578750
Drug: Transplantation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplantation of autologous noncultured epidermal cell suspension (NCES) procedure done once
Study: 35680097
Drug: Adjuvant intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intravitreal therapy with 200 mg/ml 5-Fluorouracil (5-FU) and 5 IU/ml dalteparin (low-molecular weight heparin)
Study: 35680097
Drug: Adjuvant intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intravitreal therapy with 5-FU and LMWH
Study: 34710343
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl 4 g daily
Study: 32794478
Drug: Thumb spica
Normalized name: Thumb Spica Splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thumb spica cast with methylprednisolone acetate and xylocaine injection
Study: 33141923
Drug: Firsocostat (FIR)
Normalized name: Douglas fir pollen extract
DrugBank: Firsocostat (DB16166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firsocostat (FIR) 10 mg
Study: 33141923
Drug: Firsocostat (FIR)
Normalized name: Douglas fir pollen extract
DrugBank: Firsocostat (DB16166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firsocostat (FIR) 10 mg plus rifampin (RIF) 300 mg i.v.
Study: 33141923
Drug: Rifampin (RIF)
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (RIF) 300 mg i.v. (control)
Study: 34047372
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose genistein aglycone (160 mg/kg/day)
Study: 33946072
Drug: Guided cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided cognitive-behavioral web-based intervention (WBI) + treatment as usual (TAU)
Study: 38306042
Drug: Intensive BP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive BP treatment
Study: 38306042
Drug: Standard BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP treatment
Study: 32304001
Drug: Non-surgical conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical conventional treatment and diode laser application with wavelength of 980 nm (TG)
Study: 32304001
Drug: Non-surgical conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical conventional treatment (CG)
Study: 33438442
Drug: Gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine with EPA-enriched oral supplement (1,000 mg/m2 gemcitabine on days 1, 8, and 15 every 4 weeks; EPA 1.056 mg per pack, maximum of two packs daily)
Study: 33438442
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy (1,000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Study: 33526709
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg SC every 2 weeks (q2w)
Study: 33526709
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg SC every 4 weeks (q4w)
Study: 35334418
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (n = 824)
Study: 34630613
Drug: Compound Shenlu
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Shenlu granule (SLG) supportive group (group A, n = 44)
Study: 32933356
Drug: myo-inositol supplementation
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: myo-inositol supplementation (2000 mg of myo-inositol and 200 μg of folic acid)
Study: 33377611
Drug: Ranibizumab monthly
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monthly regimen (0.5 mg) from baseline to Month 11
Study: 33377611
Drug: Ranibizumab PRN
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab PRN regimen (0.5 mg) from Month 12 to Month 23
Study: 35321000
Drug: General oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: General oxygen therapy
Study: 32043344
Drug: Carbohydrate-electrolyte-protein solution
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte-protein solution (CEPS)
Study: 35848336
Drug: OCS‐01 (dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCS‐01 (dexamethasone ophthalmic suspension), 1 drop 3 times/day for 12 weeks
Study: 35848336
Drug: OCS‐01 (dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCS‐01 (dexamethasone ophthalmic suspension)
Study: 33835383
Drug: GMB 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMB 120 mg
Study: 33835383
Drug: GMB 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMB 240 mg
Study: 33243380
Drug: TMVr with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMVr with the MitraClip plus guideline-directed medical therapy (GDMT) (n = 302)
Study: 34169381
Drug: Remote Ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Ischemic Conditioning (RIC) administered daily for up to 15 days
Study: 35523505
Drug: Multi-nutrient supplement
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient supplement (330 kcal, 20 g protein, 1.5 g calcium 3-hydroxy-3-methylbutyrate monohydrate, 449 mg calcium, 500 IU vitamin D3, and 25 vitamins and minerals)
Study: 33563049
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupuncture and medical training therapy
Study: 33563049
Drug: All intervention
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All intervention groups (including acupuncture and medical training therapy)
Study: 34224510
Drug: PO TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO TXA (1.95 g 2 hours preoperatively)
Study: 34224510
Drug: IV TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TXA (2 g: 1 g before incision and 1 g before wound closure)
Study: 34769944
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (brochure and weekly mobile phone messages for six weeks)
Study: 32212519
Drug: Fostemsavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (600 mg twice daily)
Study: 32212519
Drug: Fostemsavir plus
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir plus optimized background therapy
Study: 32212519
Drug: Open-label fostemsavir
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label fostemsavir plus optimized background therapy
Study: 35864019
Drug: Tixel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tixel treatment (thermomechanical skin device) applied across the upper and lower eyelids, three treatments with 2-week intervals.
Study: 32956698
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (Arm 3)
Study: 33443541
Drug: Sequential Chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Chemoradiation (SCRT) - cisplatin 60-75 mg/m2 plus paclitaxel 135-175 mg/m2 in a 21-day cycle, given 2 cycles before and 2 cycles after radiotherapy.
Study: 33443541
Drug: Concurrent Chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Chemoradiation (CCRT) - weekly cisplatin 30-40 mg/m2.
Study: 33443541
Drug: Radiation Alone
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation Alone (RT) - total dose 45-50 Gy.
Study: 32803438
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser treatment with fluoride varnish
Study: 34338132
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 36 µg
Study: 34338132
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 18 µg
Study: 34338132
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 9 µg
Study: 34338132
Drug: Open-label tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label tiotropium 2.5 µg
Study: 33094562
Drug: TXA (tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (tranexamic acid) 500 mg into the joint after closure, knee and hip flexed at 45° for 4 h
Study: 33124144
Drug: CD4-driven planned
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CD4-driven planned treatment interruptions (PTI)
Study: 36348453
Drug: Intensified TBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified TBM regimen (oral high-dose rifampicin 35 mg/kg daily and linezolid 1200 mg daily then 600 mg daily for the first 8 weeks)
Study: 36348453
Drug: Adjunctive aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive aspirin (200 mg daily)
Study: 36348453
Drug: WHO standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO standard TB treatment
Study: 33760026
Drug: 37% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% phosphoric acid gel etchant for 15 seconds
Study: 33504356
Drug: Online treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online treatment decision aid
Study: 32565534
Drug: High-dose S-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose S-ketamine
Study: 32928863
Drug: Beta-alanine (BA)
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NLPE training.
Study: 32928863
Drug: Beta-alanine (BA)
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NMES.
Study: 32928863
Drug: Beta-alanine (BA)
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (BA) supplementation (3.2 g per day)
Study: 34706665
Drug: GnRH-ant half-dose
Normalized name: wood ant preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-ant half-dose (Group 1)
Study: 34706665
Drug: GnRH-ant full-dose
Normalized name: wood ant preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-ant full-dose (Group 2)
Study: 33017045
Drug: Modified Kligman's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Kligman's triple combination (TC)
Study: 34583744
Drug: Real-time PRO
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time PRO data captured with electronic mobile devices, weekly requests via an app to complete the PRO survey.
Study: 33709142
Drug: Remdesivir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remdesivir (100 mg/day for 5 days)
Study: 34752935
Drug: AT-001 (caficrestat)
Normalized name: AT-III
DrugBank: AT-001 (DB15121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-001 (caficrestat) 1500 mg BID for up to 14 days
Study: 33479931
Drug: Home hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home hospital care (nurse and physician home visits, intravenous medications, remote monitoring, video communication, point‐of‐care testing)
Study: 36329548
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and advice (treatment as usual, TAU) (n = 41)
Study: 35103799
Drug: Brimonidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 2 mg/mL
Study: 35103799
Drug: Brinzolamide 10
Normalized name: brinzolamide 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 10 mg/mL
Study: 35808843
Drug: Endothelial protocol
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial protocol (Nicorandil, L-arginine, folate, Nebivolol, atorvastatin)
Study: 33357007
Drug: Salbutamol (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (16 mg/day) during resistance training
Study: 33443925
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TXA) 1300 mg per dose, three doses: 2 hours before surgery, and 6 and 12 hours after surgery.
Study: 33443925
Drug: Oral ε‐aminocaproic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ε‐aminocaproic acid (EACA) 2000 mg per dose, three doses: 2 hours before surgery, and 6 and 12 hours after surgery.
Study: 32519795
Drug: Tirzepatide (≥5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (≥5 mg for non-T2DM and ≥4.5 mg for T2DM)
Study: 32519795
Drug: Tirzepatide (5/5/10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (5/5/10/10 or 5/5/10/15 mg) in T2DM participants
Study: 32252004
Drug: rhIGF-I with
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I with oral estrogen-progesterone (EP)
Study: 35588245
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day viloxazine extended-release
Study: 33231117
Drug: Behavioral approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral approaches to aphasia treatment
Study: 33231117
Drug: Pharmacotherapy options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy options
Study: 33231117
Drug: Placebo-controlled behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled behavioral treatments
Study: 33576113
Drug: LTI-291 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTI-291 (3, 10, 30, and 90 mg single doses)
Study: 33576113
Drug: LTI-291 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTI-291 (3, 10, 30, and 60 mg multiple doses)
Study: 36074934
Drug: LED photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED photobiomodulation therapy (PBMT) with red (630 nm) and infrared (850 nm) wavelengths
Study: 36074934
Drug: Control (right
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (right side of abdomen, no treatment)
Study: 33914197
Drug: Insulin (INS)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (INS) intervention
Study: 34897211
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral placebo)
Study: 34897211
Drug: Control (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (topical placebo)
Study: 33334164
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy for insomnia (CBT-I)
Study: 35482129
Drug: 1565-nm non-ablative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1565-nm non-ablative fractional laser combined with low-dose compound betamethasone topical application
Study: 32537715
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg once-daily for 15 days
Study: 32635661
Drug: Synbiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic preparation containing Lactobacillus and Bifidobacterium strains and fructooligosaccharides
Study: 38794741
Drug: Synbiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic treatment
Study: 36067791
Drug: Premarin Vaginal
Normalized name: Premarin Vaginal
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premarin Vaginal Cream (0.625 mg/g) once daily for 3 weeks
Study: 36067791
Drug: Honglilai Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honglilai Vaginal Cream
Study: 36067791
Drug: Premarin Vaginal
Normalized name: Premarin Vaginal
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premarin Vaginal Cream
Study: 32401633
Drug: FLAG (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAG (fludarabine 30 mg/m2/dose on days 1-5; cytarabine 2000 mg/m2/dose on days 1-5; granulocyte-colony stimulating factor 5 mg/kg/dose, days 1-5 and day 15)
Study: 34563397
Drug: PCV13 vaccine
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 vaccine
Study: 35364620
Drug: Values-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Values-based cognitive behavioural therapy (V-CBT) delivered within 6 months post-injury, 10 sessions starting 1 week post-randomization (group A)
Study: 35364620
Drug: Values-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Values-based cognitive behavioural therapy (V-CBT) delivered within 6 months post-injury, 10 sessions starting 3 months post-randomization (group B)
Study: 33690227
Drug: Training data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training data group (drugs with known pharmacokinetic and physical parameters)
Study: 32952016
Drug: RedSol (reducing
Approvals — FDA: no, EMA: no, PMDA: no
Description: RedSol (reducing solution)
Study: 32505857
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL retained cystoscopy fluid
Study: 33866315
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (0.12 g)
Study: 33772416
Drug: ADHD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD treatment
Study: 35850141
Drug: Modified low
Normalized name: Minimally modified low density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified low dose protocol with tin filtering
Study: 35850141
Drug: Conventional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low dose protocol without tin filtering
Study: 34023839
Drug: Logistical regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistical regression model adjusted for tooth mobility, bone or respiratory diseases, and consumption of anxiolytics and antidepressants
Study: 35689905
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing counseling plus nicotine replacement therapy (NRT)
Study: 33067258
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment with small-size balloon predilation (pBVR<0.8)
Study: 33067258
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment with large-size balloon predilation (pBVR 0.8-1.0)
Study: 32204222
Drug: Aspirin 80mg
Normalized name: Walgreens Infants' Non-Aspirin 80mg/0.8ml Drops (Grape)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 80mg plus pravastatin 20mg twice daily until 35 weeks gestation
Study: 32204222
Drug: Aspirin 80mg
Normalized name: Walgreens Infants' Non-Aspirin 80mg/0.8ml Drops (Grape)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 80mg
Study: 35365190
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) applied once at the level of the lesion, five segments above/below, and on the plantar surface of both feet within the first 48 h after trauma (energy flux density: 0.1–0.19 mJ/mm2, frequency: 2–5 Hz)